In the HFD-induced mice NAFLD model, doses of 1, 3, and 10 mg/kg significantly reduced NAS scores and demonstrated dose-dependent decreases in LDL, TC, TG, and HDL levels, without significant impact on liver/body weight ratios, ALT, and AST. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.